KR20180105705A - 백신 보조제로서의 중간엽 줄기 세포 및 그의 사용 방법 - Google Patents

백신 보조제로서의 중간엽 줄기 세포 및 그의 사용 방법 Download PDF

Info

Publication number
KR20180105705A
KR20180105705A KR1020187025027A KR20187025027A KR20180105705A KR 20180105705 A KR20180105705 A KR 20180105705A KR 1020187025027 A KR1020187025027 A KR 1020187025027A KR 20187025027 A KR20187025027 A KR 20187025027A KR 20180105705 A KR20180105705 A KR 20180105705A
Authority
KR
South Korea
Prior art keywords
virus
protein
vaccine
adjuvant
mesenchymal stem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020187025027A
Other languages
English (en)
Korean (ko)
Inventor
조슈아 엠. 헤어
아나 마리 란딘
Original Assignee
롱에버론 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 롱에버론 엘엘씨 filed Critical 롱에버론 엘엘씨
Publication of KR20180105705A publication Critical patent/KR20180105705A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020187025027A 2016-02-04 2017-02-02 백신 보조제로서의 중간엽 줄기 세포 및 그의 사용 방법 Withdrawn KR20180105705A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662291350P 2016-02-04 2016-02-04
US62/291,350 2016-02-04
PCT/US2017/016200 WO2017136539A1 (en) 2016-02-04 2017-02-02 Mesenchymal stem cells as vaccine adjuvants and methods for using the same

Publications (1)

Publication Number Publication Date
KR20180105705A true KR20180105705A (ko) 2018-09-28

Family

ID=58261704

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187025027A Withdrawn KR20180105705A (ko) 2016-02-04 2017-02-02 백신 보조제로서의 중간엽 줄기 세포 및 그의 사용 방법

Country Status (11)

Country Link
US (2) US11975068B2 (https=)
EP (2) EP4316497A3 (https=)
JP (3) JP7814090B2 (https=)
KR (1) KR20180105705A (https=)
AU (2) AU2017213812B2 (https=)
CA (1) CA3013457A1 (https=)
ES (1) ES2960206T3 (https=)
IL (1) IL260858B (https=)
SG (1) SG11201806587RA (https=)
WO (1) WO2017136539A1 (https=)
ZA (2) ZA201805159B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020166063A1 (ja) * 2019-02-15 2020-08-20 大和薬品株式会社 フレイル改善方法およびフレイル改善食品
CN111568927A (zh) * 2020-05-23 2020-08-25 湖南源品细胞生物科技有限公司 一种msc用于调节记忆b细胞数量的应用
JP2023540096A (ja) 2020-09-08 2023-09-21 ロングエバーオン インコーポレイテッド アロジェニック間葉系幹細胞によるアルツハイマー病の治療
CN112641938A (zh) * 2020-11-22 2021-04-13 翁炳焕 一种dna重组干细胞载体新冠疫苗
US20220218817A1 (en) * 2021-01-08 2022-07-14 Vitro Biopharma, Inc. Immune modulation by mesenchymal stem cells
CN117999082A (zh) 2021-07-26 2024-05-07 美商生命科学有限公司 间充质干细胞在治疗青少年左心发育不良综合征中的用途
WO2025137077A1 (en) 2023-12-19 2025-06-26 Longeveron, Inc. Improved brain architecture and biomarkers in alzheimer's disease with mesenchymal stem cells
WO2025199451A2 (en) 2024-03-21 2025-09-25 Longeveron Inc. Mmp-14 potency assay for mesenchymal stem cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2999199A (en) 1998-04-03 1999-10-25 Osiris Therapeutics, Inc. Mesenchymal stem cells as immunosuppressants
US8554280B2 (en) 2010-03-23 2013-10-08 Ebay Inc. Free-form entries during payment processes
US10472647B2 (en) 2012-12-21 2019-11-12 The Administrators Of The Tulane Educational Fund Primary mesenchymal stem cells as a vaccine platform
WO2014100857A1 (en) 2012-12-24 2014-07-03 Cell Ideas Pty Ltd Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
US9101597B2 (en) 2013-03-14 2015-08-11 The Administration Of The Tulane Educational Fund Immunoprotective primary mesenchymal stem cells and methods
CN104138391B (zh) 2013-05-08 2018-07-31 中国科学院上海生命科学研究院 间充质干细胞在预防或治疗应激反应导致的免疫力下降中的应用

Also Published As

Publication number Publication date
CA3013457A1 (en) 2017-08-10
JP2026012755A (ja) 2026-01-27
JP2023036949A (ja) 2023-03-14
EP3411050B1 (en) 2023-09-27
WO2017136539A1 (en) 2017-08-10
AU2017213812B2 (en) 2024-04-04
SG11201806587RA (en) 2018-09-27
EP4316497A2 (en) 2024-02-07
JP2019509264A (ja) 2019-04-04
ES2960206T3 (es) 2024-03-01
US20190038742A1 (en) 2019-02-07
AU2024204598A1 (en) 2024-07-18
ZA202000574B (en) 2021-08-25
EP3411050A1 (en) 2018-12-12
ZA201805159B (en) 2020-10-28
EP4316497A3 (en) 2024-05-01
US11975068B2 (en) 2024-05-07
IL260858B (en) 2022-04-01
AU2017213812A1 (en) 2018-08-16
IL260858A (en) 2018-10-31
US20240252627A1 (en) 2024-08-01
JP7814090B2 (ja) 2026-02-16

Similar Documents

Publication Publication Date Title
US20240252627A1 (en) Mesenchymal stem cells as vaccine adjuvants and methods for using the same
JP7491964B2 (ja) 細胞性及び体液性免疫を達成するためのヒト間葉系幹細胞を使用する方法
Jabbari et al. Secondary memory CD8+ T cells are more protective but slower to acquire a central–memory phenotype
Ross et al. Single dose combination nanovaccine provides protection against influenza A virus in young and aged mice
WO2023280835A1 (en) Mesenchymal stem cells for use in the treatment of chronic gingivostomatitis
Ivanova et al. Anti-Asialo GM1 treatment during secondary Toxoplasma gondii infection is lethal and depletes T cells
HK40109512A (zh) 使用人类间充质干细胞以实现细胞免疫及体液免疫的方法
KR100735083B1 (ko) Ｃｄ8 ｔ 세포 활성화 방법
Gonzaga et al. Non-Viral Therapy in COVID-19: Where Are We Standing? Towards Cell Therapy Approaches for Long COVID Patients
McEwen-Smith An investigation into the regulatory capacity of invariant natural killer T (iNKT) cells during the innate and adaptive immune response to influenza infection
Gasper Cell-Mediated Antiviral Immunity And Host Responses to CD8 T-cell Vaccines and Respiratory Virus Infection

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PC1202 Submission of document of withdrawal before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1202